secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-108192
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027
--------------------------------------------------------------------------------

- Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
- SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.
- Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.
- Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.
- No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/0001213900-25-108192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/ea0264778-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer